pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 44 Non-oncology: 29
Oncology: 15
Under Consideration for Negotiation 23 Non-oncology: 13
Oncology: 10
Completed Negotiations 460 With Letter of Intent: 399
Without agreement: 61
Negotiations That Were Not Pursued 86

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Luxturna Novartis Pharmaceuticals Canada Inc. Inherited retinal disease
pdp-levETIRAcetam Pendopharm Epilepsy
Tecartus Gilead Sciences Canada Inc. For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi)
Entuzity KwikPen Eli Lilly Canada Inc. Diabetes Mellitus, Type 1 & 2
Veltassa Otsuka Canada Pharmaceuticals Inc. hyperkalemia
Unituxin United Therapeutics high-risk neuroblastoma patients in their first relapse or determination of refractory disease, in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor
Zaxine Lupin Pharma Canada Limited Hepatic Encephalopathy

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Polivy HOFFMANN-LA ROCHE LIMITED In combo with bendamustine & rituximab is indicated for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, who are not eligible for autologous stem cell transplant & have received at least one prior therapy.
Duobrii Bausch Health, Canada Inc. Psoriasis, moderate to severe plaque
Baqsimi Eli Lilly Canada Inc. severe hypoglycemia
Forxiga AstraZeneca Canada Inc. Heart failure, NYHA class II or III

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Saxenda Novo Nordisk Canada Inc. chronic weight management